In order to seek vancomycin analogs with improved performance against VanA and VanB resistant bacterial strains, extensive computational investigations have been performed to examine the effects of side-chain and backbone modifications. Changes in binding affinities for tripeptide cell-wall precursor mimics, Ac(2)-l-Lys-d-Ala-d-Ala (3) and Ac(2)-l-Lys-d-Ala-d-Lac (4), with vancomycin analogs were computed with Monte Carlo/free energy perturbation (MC/FEP) calculations. Replacements of the 3-hydroxyl group in residue 7 with small alkyl or alkoxy groups, which improve contacts with the methyl side chain of the ligands'd-Ala residue, are predicted to be the most promising to enhance binding for both ligands. The previously reported amine backbone modification as in 5 is shown to complement the hydrophobic modifications for binding monoacetylated tripeptides. In addition, replacement of the hydroxyl groups in residues 5 and 7 by fluorine is computed to have negligible impact on binding the tripeptides, though it may be pharmacologically advantageous.
In order to seek vancomycin analogs with improved performance against n class="Chemical">VanA and VanB resistant bacterial strains, extensive computational investigations have been performed to examine the effects of side-chain and backbone modifications. Changes in binding affinities for tripeptide cell-wall precursor mimics, Ac(2)-l-Lys-d-Ala-d-Ala (3) and Ac(2)-l-Lys-d-Ala-d-Lac (4), with vancomycin analogs were computed with Monte Carlo/free energy perturbation (MC/FEP) calculations. Replacements of the 3-hydroxyl group in residue 7 with small alkyl or alkoxy groups, which improve contacts with the methyl side chain of the ligands'd-Ala residue, are predicted to be the most promising to enhance binding for both ligands. The previously reported amine backbone modification as in 5 is shown to complement the hydrophobic modifications for binding monoacetylated tripeptides. In addition, replacement of the hydroxyl groups in residues 5 and 7 by fluorine is computed to have negligible impact on binding the tripeptides, though it may be pharmacologically advantageous.
Authors: Michael R Leadbetter; Stacy M Adams; Bettina Bazzini; Paul R Fatheree; Dane E Karr; Kevin M Krause; Bernice M T Lam; Martin S Linsell; Matthew B Nodwell; John L Pace; Kelly Quast; Jeng-Pyng Shaw; Elizabeth Soriano; Sean G Trapp; Jenny D Villena; Terry X Wu; Burton G Christensen; J Kevin Judice Journal: J Antibiot (Tokyo) Date: 2004-05 Impact factor: 2.649
Authors: Jian Xie; Akinori Okano; Joshua G Pierce; Robert C James; Simon Stamm; Christine M Crane; Dale L Boger Journal: J Am Chem Soc Date: 2012-01-06 Impact factor: 15.419
Authors: Christine M Crane; Joshua G Pierce; Siegfried S F Leung; Julian Tirado-Rives; William L Jorgensen; Dale L Boger Journal: J Med Chem Date: 2010-10-14 Impact factor: 7.446
Authors: Alexandra Antonoplis; Xiaoyu Zang; Melanie A Huttner; Kelvin K L Chong; Yu B Lee; Julia Y Co; Manuel R Amieva; Kimberly A Kline; Paul A Wender; Lynette Cegelski Journal: J Am Chem Soc Date: 2018-11-14 Impact factor: 15.419